HEALEY ALS Platform Trial
This is the first ALS platform trial, accelerating the path to new ALS therapies by testing multiple treatments at once, reducing the cost of research by 30%, decreasing the trial time by 50% and increasing patient participation by 67%
Site PI: Dr. E. Young
Study Coordinator: Lena Deb (DebL@upstate.edu; 315-464-9756)
COMBAT - ALS
A phase 2b/3 Multi-center, Randomized, Double-blind, placebo-controlled, 12 month clinical trial to evaluate the efficacy and safety of MN-166 (ibudilast) followed by an open-label extension in subjects with ALS.
A study measuring the safety and efficacy of Ibudilast (MN-166) for use in ALS. This drug has already shown promise in ALS in its phase 2 trial in improving patient’s functional activity, quality of life and muscle strength.
Site PI: Dr. J. Meyer
Study Coordinator: Marielle De Masi (DemasiM@upstate.edu; 315-464-1670)
If you are interested in getting information about any of the above studies, please contact our Clinical Research Coordinators Directly.